SCHEMBL1240887

SCHEMBL1240887

CCOC(=O)CNS(=O)(=O)c1cnc(NC(C)=O)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 6/20 0.55
CDK2 P24941 6/20 0.55
CDK4 P11802 5/20 0.55
CCNE2 O96020 5/20 0.55
CDK1 P06493 4/20 0.55
CCND1 P24385 4/20 0.55
CCNB2 O95067 3/20 0.55
CCNB1 P14635 3/20 0.55
CCNB3 Q8WWL7 3/20 0.55
ALDH1A1 P00352 5/20 0.41
TSHR P16473 1/20 0.41
HPGD P15428 1/20 0.40
S1PR1 P21453 1/20 0.40
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.37
STAT1 P42224 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1240657 0.81 SMN1; SMN2 (0.53) ALDH1A1TSHRHPGDPKMSMN1; SMN2
SCHEMBL2650389 0.80 ALDH1A1 (0.40) CCNE1CDK2CDK4CCNE2CDK1
SCHEMBL10154046 0.76 CA12 (0.54) CCNE1CDK2CDK4CCNE2CDK1
SCHEMBL15882463 0.76 CCNE1 (0.44) CCNE1CDK2CDK4CCNE2CDK1
SCHEMBL16731877 0.76 CCNE1 (0.49) CCNE1CDK2CDK4CCNE2CDK1
SCHEMBL20656520 0.75 CCNE1 (0.46) CCNE1CDK2CDK4CCNE2CDK1
SCHEMBL969054 0.74 ALDH1A1 (0.43) ALDH1A1TSHRHPGDMAPTPKM
SCHEMBL1238692 0.74 TP53 (0.33) CCNE1CDK2CDK4CCNE2CDK1
SCHEMBL1238688 0.74 TP53 (0.33) CCNE1CDK2CDK4CCNE2CDK1
SCHEMBL14419937 0.72 FFAR2 (0.52) CCNE1CDK2CDK4CCNE2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586614-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-11-19 US disclosed
US-20110077234-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2011-03-31 US disclosed
US-7884210-B2 {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes NOVO NORDISK A/S (DK) 2011-02-08 US disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
US-20090105482-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
EP-1904467-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006814-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 CCNE1 2454/4885CDK2 253/4885CDK4 519/4885
US-20090105482-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CCNE1 2561/4885CDK2 268/4885CDK4 705/4885
US-20110077234-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CCNE1 2561/4885CDK2 268/4885CDK4 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.